Skip to contentP
Pulse Biosciences, Inc.
P
PLSEPulse Biosciences, Inc. Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$264.00K$264.00Kderived— vs Q4 2024 Net Income-$17.43M-$17.43MderivedN/M vs Q4 2024 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pulse Biosciences, Inc. · CIK 1625101 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$18,253,000N/M Operating Cash Flowderived-$14,755,000N/M Free Cash Flowderived-$14,860,000N/M Margins · derivedOperating margin-6914.0%
Net margin-6603.4%
ended Dec 31, 2025 · filed Feb 19, 2026 · 50 d after period end